Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24941938 | 0.85 | — | — | |
| SCHEMBL20345513 | 0.84 | HRH3 (0.33) | HRH3CYP2D6 | |
| SCHEMBL26143199 | 0.84 | LMNA (0.32) | — | |
| SCHEMBL22650310 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL21784584 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL21786323 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL22142562 | 0.80 | CHRM1 (0.35) | HRH3CYP2D6 | |
| SCHEMBL25089956 | 0.79 | KDM4E (0.36) | — | |
| SCHEMBL24865916 | 0.78 | — | — | |
| SCHEMBL25089954 | 0.77 | HRH3 (0.32) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2023283263-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | HRH3 2752/4885CYP2D6 2726/4885 |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | HRH3 2014/4885CYP2D6 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.